CDK4 and cancer: As one illustration, a comprehensive multi-omics study of CDK4/6 inhibitor response in cancer cells revealed networks of downstream and off-target effects, suggesting additional nodes (beyond CDK4/6) that a polypharmacological drug might modulate to improve efficacy [20].